

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



Q-LINE BIOTECH LIMITED

CIN: U74120UP2010PLC042528

Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled **"History and Corporate Structure"** beginning on page 149 of the Draft Red Herring Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012
Tel.: +91 522-2435570, **E-mail:** compliance@qlinebiotech.com, **Website:** www.qlinebiotech.com
Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer

OUR PROMOTERS: Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal

“THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (“NSE EMERGE”).”

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 70,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF Q-LINE BIOTECH LIMITED ("OUR COMPANY" OR "QLBL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹ (●) PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ (●) LAKHS ("PUBLIC ISSUE") OUT OF WHICH (●) EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING ₹ (●) LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF (●) EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ (●) LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE (●) % AND (●) % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, MAY CONSIDER A PRE-IPO PLACEMENT OF UP TO 8,00,000 EQUITY SHARES FOR CASH CONSIDERATION ("PRE-IPO PLACEMENT") PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS. IF THE PRE-IPO PLACEMENT IS UNDERTAKEN, THE NUMBER OF EQUITY SHARES ISSUED PURSUANT TO THE PRE-IPO PLACEMENT SHALL BE REDUCED FROM THE ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B)(I) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED ("SCRR").

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLMs AND WILL BE ADVERTISED IN ALL EDITION OF (●) (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND ALL EDITION OF (●) (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND HINDI EDITION OF (●), REGIONAL NEWSPAPER (HINDI BEING THE REGIONAL LANGUAGE OF LUCKNOW WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF NSE ("NSE EMERGE ") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least 3 additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of 1 Working Day, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLMs and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (of which one third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs) and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders who applies for minimum application size, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see **"Issue Procedure"** beginning on page 344 of the Draft Red Herring Prospectus.

This public announcement is made in compliance with the provisions of Regulation 247(2) of the SEBI ICDR Regulations, to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares of face value of ₹ 10 each pursuant to the issue and the Draft Red Herring Prospectus dated September 30, 2025 has been filed with the SME Platform of NSE ("NSE Emerge") on September 30, 2025. The Draft Red Herring Prospectus filed with NSE Emerge shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents/sme_offer, on the website of the BRLMs at www.hemsecurities.com and www.shareindia.com and also on the website of the Company www.qlinebiotech.com. Our Company invites public to give comments on the Draft Red Herring Prospectus filed with NSE Emerge with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of our Company, and/or to the BRLMs at their respective addresses mentioned below. All comments must be received by our Company and/or the Company Secretary & Compliance Officer of our Company, and/or to the BRLMs in relation to the issue on or before 5.00 p.m. on the 21st day after the aforementioned date of filing of the Draft Red Herring Prospectus with NSE Emerge.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to **"Risk Factors"** on page 29 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the Registrar of Companies ("RoC") and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of NSE ("NSE Emerge"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see **"Capital Structure"** beginning on page 71 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see **"History and Corporate Structure"** beginning on page 149 of the Draft Red Herring Prospectus.

The BRLMs associated with the Issue have handled 87 Public Issues in the past three years, out of which 8 issues were closed below the Issue/ Offer Price on listing date:

| Name of BRLM | Total Issue | | Issue closed below IPO Price on listing date |
|--|-------------|-----|--|
| | Mainboard | SME | |
| Hem Securities Limited | 2 | 66 | 3 (SME) |
| Share India Capital Services Private Limited | - | 18 | 5 |
| Common* | - | 1 | - |
| Total | 2 | 85 | 8 |

*Issues in which both BRLMs were involved.

| BOOK RUNNING LEAD MANAGERS TO THE ISSUE | | REGISTRAR TO THE ISSUE |
|--|---|---|
| | | |
| HEM SECURITIES LIMITED Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai - 400013, Maharashtra, India Tel. No.: +91- 22- 49060000; Email: ib@hemsecurities.com Investor Grievance Email: redressal@hemsecurities.com Website: www.hemsecurities.com Contact Person: Sourabh Garg, VP SEBI Regn. No.: INM000010981 | SHARE INDIA CAPITAL SERVICES PRIVATE LIMITED Address: A-25, Basement, Sector-64, Noida, Gautam Buddha Nagar, 201301, Uttar Pradesh, India Tel No.: +91 0120-6483000 Email: mb@shareindia.com Website: www.shareindia.com Contact Person: Kunal Bansal SEBI Reg. No.: INM000012537 | PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011 Tel. No.: 91 22 2301 2517 / 8261 Fax No.: +91-022-23012517 Email: support@purvashare.com Website: www.purvashare.com Contact Person: Deepali Dhuri SEBI Registration No.: INR000001112 |

COMPANY SECRETARY & COMPLIANCE OFFICER

Akhand Pratap Singh, Company Secretary & Compliance Officer,
Tel.: +91 522-2435570, **E-mail:** akhand.singh@qlinebiotech.com, **Website:** www.qlinebiotech.com
Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Red Herring Prospectus.

Place: Lucknow
Date: October 01, 2025

For Q-Line Biotech Limited
On behalf of the Board of Directors
Sd/-
Akhand Pratap Singh
Company Secretary and Compliance Officer

Disclaimer: Q-Line Biotech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on September 30, 2025. The Draft Red Herring Prospectus is available on the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents/sme_offer and is available on the websites of the BRLMs at www.hemsecurities.com and www.shareindia.com and also on the website of the Company www.qlinebiotech.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 29 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.



(Please scan this QR Code to view the DRHP)

| ALPHA FINTECH PRIVATE LIMITED (CIN: UH120MH2015PTC273399) Registered Office: Unit No. 1023, 12th floor, B-Wing, The Capital, Plot No. C-70, G Block, BKC, Mumbai City, Mumbai - 400050, Maharashtra, India Contact No.: 022-6488 6100 Email: incrd.compliance@incrd.com Website: https://www.incrdmoneym.com/ | BOOTH FINTECH PRIVATE LIMITED (Currently known as 'IncRed Techninvest Private Limited') CIN: U66309MH2015PTC355907 Registered Office: Unit No. 1023, 12th Floor, B-Wing, The Capital, Bandra-Kurla Complex, Mumbai - 400005, Maharashtra, India Contact No.: 022-6488 6100 Email: incrd.compliance@incrd.com | | | | | | | | | | |
|---|--|---|------------------|----------|--|--------------|--------------------------|-------------------------------------|-----------------------------|-----------------------------------|--------------------------|
| Form CAA-2 (Pursuant to Section 230(3) and Rule 6 and Rule 7 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016) | | | | | | | | | | | |
| IN THE NATIONAL COMPANY LAW TRIBUNAL, BENCH AT MUMBAI C.A. (CAA) / 123 / MB / 2025 | | | | | | | | | | | |
| In the matter of the Companies Act, 2013; AND In the matter of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules framed thereunder; AND In the matter of scheme of amalgamation between Alpha Fintech Private Limited (Transferor Company or Applicant Company 1) and Booth Fintech Private Limited, currently known as, 'IncRed Techninvest Private Limited' (Transferee Company or Applicant Company 2) and their respective shareholders (hereinafter referred to as the 'Scheme' or 'Scheme of Amalgamation') | | | | | | | | | | | |
| Alpha Fintech Private Limited, a private company incorporated under the Companies Act, 2013 and having its registered office address at Unit No. 1023, 12th Floor, B-Wing, The Capital, Plot No C-70, G Block, Bandra - Kurla Complex, Bandra (East), Mumbai - 400005, Maharashtra, India CIN: UH120MH2015PTC273399 | Transferee Company / Applicant Company 2 (Collectively known as the Applicant Companies for the sake of brevity) | | | | | | | | | | |
| Booth Fintech Private Limited, currently known as, 'IncRed Techninvest Private Limited', a private company incorporated under the Companies Act, 2013 and having its registered office address at Unit No. 1023, 12th Floor, B-Wing, The Capital, Bandra - Kurla Complex, Mumbai - 400005, Maharashtra, India CIN: U66309MH2015PTC355907 | Transferee Company / Applicant Company 2 (Collectively known as the Applicant Companies for the sake of brevity) | | | | | | | | | | |
| Notice and Advertisement of the NCLT convened meetings of the Equity Shareholders of the respective Applicant Companies and Preference Shareholders of the Applicant Company 2 | | | | | | | | | | | |
| NOTICE is hereby given that by an order dated July 14, 2025 in the above mentioned Company Scheme Application (Order), the Hon'ble National Company Law Tribunal, Mumbai Bench (Hon'ble Tribunal or NCLT) has directed the meetings of the Equity Shareholders of the respective Applicant Companies and Preference Shareholders of Applicant Company 2, be convened and held to consider, and if thought fit, to approve the proposed Scheme of amalgamation between Alpha Fintech Private Limited (Transferor Company or Applicant Company 1) and Booth Fintech Private Limited (currently known as, 'IncRed Techninvest Private Limited' (Transferee Company or Applicant Company 2)) and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules framed thereunder (hereinafter referred to as the 'Scheme' or 'Scheme of Amalgamation'). | | | | | | | | | | | |
| In pursuance of the Order and as directed therein, notice of the meetings of the Equity Shareholders of the respective Applicant Companies and Preference Shareholders of Applicant Company 2 along with corresponding annexures has been sent to the Shareholders of the Applicant Companies by e-mail at their registered e-mail addresses by the respective Applicant Companies. Further, in pursuance of the said order, notice is hereby given that the meetings of the Equity Shareholders of the respective Applicant Companies and Preference Shareholders of Applicant Company 2 will be held through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) mode, following the operational procedures (with the relevant modifications as may be required) referred to in Circular No. 14 / 2020 dated April 8, 2020, No. 17 / 2020 dated April 13, 2020, No. 22 / 2020 dated June 15, 2020, No. 33 / 2020 dated September 28, 2020, No. 39 / 2020 dated December 31, 2020, No. 10 / 2021 dated June 23, 2021, No. 20 / 2021 dated December 8, 2021, No. 3 / 2022 dated May 5, 2022, No. 11 / 2022 dated December 28, 2022, No. 09 / 2023 dated September 25, 2023, No. 09 / 2024 dated September 9, 2024, No. 09 / 2025 dated September 22, 2025 (MCA Circulars) issued by the Ministry of Corporate Affairs, Government of India and in compliance with the applicable laws, as under, and the shareholders of the respective Applicant Companies are requested to attend. | | | | | | | | | | | |
| Sr. No. | Meeting | Day and Date of Meetings | Time | | | | | | | | |
| 1 | Equity shareholders of the Applicant Company 1 | Monday, November 3, 2025 | 10.00 A.M. (IST) | | | | | | | | |
| 2 | Equity shareholders of the Applicant Company 2 | | 11.30 A.M. (IST) | | | | | | | | |
| 3 | Preference shareholders of the Applicant Company 2 | | 02.30 P.M. (IST) | | | | | | | | |
| Copies of the Scheme and the explanatory statement under Sections 230 and 232 read with Section 102 of the Companies Act, 2013 (Act) read with Rule 6 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and accompanying documents can be accessed / downloaded from the website of the Applicant Company 1 i.e. https://www.incrdmoneym.com/ or the website of the NSDL, i.e., https://www.evoting.nsdl.com/ and can also be obtained free of charge at the registered office of the respective Applicant Companies. Alternatively, a request for obtaining an electronic copy of the notice and other documents (as mentioned above) may be made by writing an email at incrd.compliance@incrd.com to the respective Applicant Companies. | | | | | | | | | | | |
| Since the meetings of the Equity Shareholders of the respective Applicant Companies and Preference Shareholders of Applicant Company 2 are being held as per the directions of the NCLT through VC / OAVM facility, the physical attendance of the shareholders of the respective Applicant Companies have been dispensed with. Hence, please note that the facility of appointing proxies will not be available. However, a body corporate is entitled to appoint a representative for the purposes of participating in and / or voting during the respective meetings provided the prescribed form / authorization is filed with the respective Applicant Companies at incrd.compliance@incrd.com , not later than 48 (Forty eight) hours before the start of the aforesaid meeting. | | | | | | | | | | | |
| The Hon'ble NCLT has appointed Mr. L.N. Gupta, IAS(R) and Former Member NCLT to be the Chairperson of the meetings of the equity shareholders of the respective Applicant Companies and preference shareholders of the Applicant Company 2. | | | | | | | | | | | |
| Further, Mr Bharat Upadhyay (Membership No F5436 / COP 4457) is appointed as the Scrutinizer of the aforesaid meetings of the shareholders of the Applicant Companies. | | | | | | | | | | | |
| The quorum for the meeting of the respective class of shareholders of Applicant Companies shall be (Two) shareholders. In case the required quorum is not present at the commencement of the respective meeting, the relevant meeting shall be adjourned by 30 minutes and thereafter the persons present shall be deemed to constitute the quorum for the respective meeting. | | | | | | | | | | | |
| The shareholders of the Applicant Companies shall have the facility and option of voting on the resolution for approval of the Scheme by casting their votes: (a) by e-voting from any place other than voting at the respective meeting; (Remote E-voting) during the period as stated below: | | | | | | | | | | | |
| <table><tr><th colspan="2">Meetings</th></tr><tr><td>Cut-off Date</td><td>Monday, October 27, 2025</td></tr><tr><td>Remote e-voting start date and time</td><td>Wednesday, October 29, 2025</td></tr><tr><td>Remote e-voting end date and time</td><td>Sunday, November 2, 2025</td></tr></table> | | | | Meetings | | Cut-off Date | Monday, October 27, 2025 | Remote e-voting start date and time | Wednesday, October 29, 2025 | Remote e-voting end date and time | Sunday, November 2, 2025 |
| Meetings | | | | | | | | | | | |
| Cut-off Date | Monday, October 27, 2025 | | | | | | | | | | |
| Remote e-voting start date and time | Wednesday, October 29, 2025 | | | | | | | | | | |
| Remote e-voting end date and time | Sunday, November 2, 2025 | | | | | | | | | | |
| Or, (b) through e-voting system available during the respective meetings to be held through VC / OAVM (E-voting at the Meeting) on Monday, November 3, 2025, if they have not cast their vote through Remote E-voting. | | | | | | | | | | | |
| The facility for voting during the respective meeting shall be available to those who attend the meeting, and who have not already cast their vote by Remote E-voting, for a duration of 15 minutes after the conclusion of the respective meeting. The shareholders of the Applicant Companies may participate at the respective meeting even after exercising his / her right to vote through Remote E-voting but shall not be allowed to vote again at the meeting. | | | | | | | | | | | |
| A person whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as the above-mentioned cut-off date i.e. Monday, October 27, 2025 shall only be entitled to exercise his / her / its voting rights on the resolution proposed in the notice and attend the respective meeting. The voting right of the shareholders shall be in proportion to their share in the paid-up share capital of the respective Applicant Company as on the cut-off date i.e. Monday, October 27, 2025. | | | | | | | | | | | |
| Members holding shares in physical mode: (i) whose email address are not registered with the respective Applicant Companies, can get their email address registered; or (ii) who may want to change their email ID registered, can get the same done, by sending an email to incrd.compliance@incrd.com for the respective Applicant Companies. | | | | | | | | | | | |
| Members holding shares in dematerialized mode, who have not registered their email addresses with their depository participant(s) are requested to register / update their email addresses with the depository participant(s) with whom they maintain their demat accounts. | | | | | | | | | | | |
| Any person, who becomes a member of the respective Applicant Companies after the date of dispatch of notice and holds shares as on the cut-off date (as specified above) can send a requisition quoting her / his Regd. Folio No. / DP ID / Client ID to get his / her login ID and password by sending a request at evoting@nsdl.com . | | | | | | | | | | | |
| Queries / grievances, if any, with regard to remote e-voting, may be addressed to Ms Nikita Shetty, Authorised Signatory for the Applicant Companies, at the registered office address of the Applicant Companies or through email at incrd.compliance@incrd.com or you may refer the Frequently Asked Questions (FAQs) for equity shareholders and e-voting user manual is available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request to NSDL at evoting@nsdl.com . | | | | | | | | | | | |
| The above-mentioned Scheme, if approved by the Equity Shareholders of the respective Applicant Companies and Preference Shareholders of the Applicant Company 2, will be subject to the subsequent approval of the Hon'ble NCLT and any other regulatory authority as may be deemed necessary. | | | | | | | | | | | |
| Dated this 2nd day of October, 2025 Place: Delhi, India | | IAS (R) and Former Member NCLT Chairperson appointed for the Meetings of Applicant Companies | | | | | | | | | |



Cello World Limited

Corporate Office: Cello House, Corporate Avenue, 'B' Wing, 8th Floor, Sonawala Road, Goregaon (East), Mumbai-400 063, India.
Tel: 022 6997 0000, **E-mail:** grievance@celloworld.com
Website: www.corporate.celloworld.com **CIN:** L25209DD2018PLC009865
Regd. Office: 597/2A, Somnath Road, Dabhel, Nani Daman, Daman & Diu - 396 210, (India)

POSTAL BALLOT NOTICE TO THE MEMBERS OF THE COMPANY

Notice is hereby given that the resolutions set out below are proposed for approval by the members of **Cello World Limited ("the Company")** by means of Postal Ballot, only by remote e-voting process ("**e-voting**") being provided by the Company to all its members to cast their votes electronically, pursuant to Sections 108 and 110 of the Companies Act, 2013 ("**the Act**"), Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014 ("**the Rules**") and other applicable provisions of the Act and the Rules, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 09/2024 dated September 19, 2024, issued by the Ministry of Corporate Affairs ("**MCA Circulars**"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**Listing Regulations**"), Secretarial Standard on General Meetings ("**SS-2**") issued by the Institute of Company Secretaries of India and other applicable laws, rules and regulations including any statutory modification(s) or re-enactment(s) thereof for the time being in force approval of the members of the Cello World Limited is being sought for the Ordinary Resolutions by way of Postal Ballot through remote E- Voting process only as set out in Postal Ballot Notice dated October 01, 2025. The Notice is available on the Company's Website at www.corporate.celloworld.com on the Website of the Stock Exchange i.e. BSE Limited at www.bseindia.com and NSE Limited at www.nseindia.com in compliance with the aforesaid provisions and MCA Circulars, electronic copy of the Postal Ballot Notice along with the Explanatory Statement have been sent through e-mail to all the members who have registered their e-mail IDs with Depository Participant / Company/Registrar & Share Transfer Agent as on **September 26, 2025** (Cut-Off Date). All members are hereby informed that

- 1) Date of Completion of Dispatch of Notice is October 01, 2025.
- 2) In terms of General Circulars issued by MCA, no physical ballot form is being dispatched by the Company and members can cast their votes using remote E-Voting facility only.
- 3) Members holding Equity Shares as on the Cut-off date are only entitled to cast their vote by remote E-Voting facility. Any person who is not a member on the cut-off date, should treat this Notice for information purpose only. The Company has engaged the services of MUFG Intime India Private Limited-MIPL (RTA) for providing remote e-voting facility to its members.
- 4) The members holding shares in Physical form and whose e-mail address are not registered with the Company as on the cut-off date are requested to register the same by sending an e-mail to the RTA at rt.helpdesk@in.mpmfug.com and to the Company at grievance@celloworld.com with the name of the Registered Shareholder(s), folio number(s), / DPN ID/Client ID and number of equity shares held from the e-mail address they wish to register to enable them to exercise their vote.
- 5) Members holding the shares in the Dematerialized mode are requested to register/update their e-mail ID with the relevant Depository Participants with whom they maintain their demat account(s).
- 6) Remote E-Voting facility will be available, please refer the instructions mentioned in the Notice for the same.
- 7) Pursuant to the Rule 22(5), the Board of Directors of the Company vide passing of Circular Resolution on October 01, 2025 have appointed Mr. Dharmesh Sarvaiya, Practicing Company Secretary (Membership No.: F11454) of M/s Sarvaiya & Co, Practicing Company Secretaries, as a Scrutiniser for conducting the Postal Ballot through e-voting process in a fair and transparent manner.
- 8) **The E-Voting shall commence on Thursday, October 02, 2025 at 09:00 a.m.** and will end on Friday, October 31, 2025 at 05:00 p.m. The voting shall not be allowed beyond the time specified.
- 9) Once the vote is cast on the resolution, the member will not be allowed to change it subsequently or cast vote again.
- 10) The resolutions, if approved, will be taken as having been duly passed on the last day specified for E-Voting i.e. Friday, October 31, 2025.
- 11) The results of Postal Ballot will be announced within 2 working days from the date of closing of e-voting on the Website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and NSE Limited at www.nseindia.com and on the Website of the company at www.corporate.celloworld.com and on the Website of RTA at www.in.mpmfug.com
- 12) In case members having any queries regarding e-voting, they may refer (i) Frequently Asked Questions (FAQs) (ii) Contact: MUFG Intime India Private Limited, C 101, 247 Park, L. B. S. Marg, Vikhroli-West, Mumbai-400083, Maharashtra, India or send a notice to enotices@in.mpmfug.com or contact on Tel: 022 - 4918 6000.

By Order of Board of Directors
Cello World Limited
Sd/-
Hemangi Trivedi
Company Secretary and Compliance Officer

Date: 01/10/2025
Place: Mumbai



कारोबार विभाजन के बाद

टाटा मोटर्स के शेयरों में उठा-पटक संभव

सोहिनी दास
मुंबई, 1 अक्टूबर

टाटा मोटर्स के वाणिज्यिक वाहन (सीवी) और यात्री वाहन (पीवी) कारोबारों के अलग होने से इसके शेयर में निकट भविष्य में उतार-चढ़ाव दिख सकता है। विश्लेषकों ने यह अनुमान जताया है। टाटा मोटर्स के ये दोनों वाहन कारोबारी खंड 1 अक्टूबर से अलग हो गए हैं। कंपनी का शेयर 30 सितंबर को बीएसई में कारोबार के दौरान 5.54 प्रतिशत तक उछल गया और बाद में 718.15 रुपये पर बंद हुआ था। अब कंपनी की दो अलग-अलग सूचीबद्ध इकाइयां होंगी। सीवी कारोबार टाटा मोटर्स कॉर्पोरेशन लिमिटेड (टीएमएलसीवी) का हिस्सा हो जाएगा जबकि ईवी और जेएलआर सहित पीवी कारोबार टाटा मोटर्स का हिस्सा हो जाएगा। कारोबार अलग होने से आने वाले समय में कंपनी को फायदा होगा। टाटा मोटर्स के चेयरमैन एन चंद्रशेखरन ने कहा था, 'कारोबार अलग होने से हमें बाजार के अवसरों का बेहतर लाभ उठाने में मदद मिलेगी।'

शेयर हकदारी अनुपात 1:1 होगा यानी टाटा मोटर्स के शेयरधारकों के पास दोनों कंपनियों में समान हिस्सेदारी रहेगी जिससे उनका स्वामित्व अपरिवर्तित रहेगा। जेएम फाइनेंशियल ने कहा कि टाटा मोटर्स 14 अक्टूबर 2025 की अस्थायी रिकॉर्ड तिथि के साथ एक रणनीतिक कारोबारी विभाजन से गुजरने के लिए तैयार है। विश्लेषकों ने कहा, 'रिकॉर्ड तारीख के बाद सीवी खंड सूचीबद्ध इकाई (टाटा मोटर्स लिमिटेड) से अलग हो जाएगा जिससे शेयर में उतार-चढ़ाव दिख सकता है।' नई गठित सीवी इकाई सभी नियामकों से मंजूरी मिलने के लगभग 30 दिन बाद नवंबर की शुरुआत तक सूचीबद्ध होने की उम्मीद है। सीवी कारोबार की



विश्लेषकों को अनुमान

■ जेएलआर के उत्पादन शुरू होने पर भी रहेगी नजरें

■ टाटा मोटर्स के वाणिज्यिक एवं यात्री वाहन खंड 1 अक्टूबर से हो गए अलग

■ अब कंपनी की दो अलग-अलग सूचीबद्ध इकाइयां होंगी

■ कंपनी का शेयर मंगलवार को बीएसई में कारोबार के दौरान 5.54 फीसदी तक उछल गया था

सूचीबद्धता के बाद इसका नाम बदल कर टाटा मोटर्स लिमिटेड रख दिया जाएगा, जबकि पीवी कारोबार टाटा मोटर्स पैसेंजर व्हीकल्स लिमिटेड (टीएमपीवी) नाम से जानी जाएगी। इस बात पर भी नजरें टिकी होंगी कि जगुआर लैंड रोवर 31 अगस्त को साइबर हमले की घटना के बाद उत्पादन कितनी शिद्वत के साथ जारी रख सकता है। जेएम फाइनेंशियल के विश्लेषकों ने कहा कि वैसे तो अमेरिका, ब्रिटेन और चीन में मांग स्थिर है लेकिन नकदी की स्थिति तो जरूर प्रभावित होगी। जहां तक सीवी कारोबार की बात है तो नई जीएसटी दरें प्रभावी होने से छोटे सीवी खंड को लाभ मिल सकता है जहां खरीदार इनपुट-टैक्स-क्रेडिट (आईटीसी) का दावा नहीं करते हैं। जेएम फाइनेंशियल ने कहा कि वित्त वर्ष 2026 की दूसरी छमाही में दो अंक की वृद्धि होने की संभावना है जिसमें त्योहारों मांग और जीएसटी में कमी की अहम भूमिका होगी। नोमुरा के विश्लेषकों ने कहा कि कंपनी प्रबंधन को उम्मीद है कि जीएसटी में कमी से सीवी कारोबार

को मदद मिलेगी क्योंकि ट्रक अधिक किफायती हो जाएंगे और माल ढुंलाई कारोबार भी रफ्तार पकड़ लेगा। नोमुरा ने कहा, 'सीवी उद्योग के वित्त वर्ष 26 में लगभग 5 प्रतिशत अनुमानित सालाना बढ़ोतरी की संभावना है, जिसका मतलब है कि वित्त वर्ष 26 की दूसरी छमाही में 10 प्रतिशत सालाना वृद्धि होगी काफी जो सकारात्मक है।' जीएसटी में कमी के बाद पीवी खंड के लिए त्योहारों की बुकिंग में 25-30 प्रतिशत की वृद्धि हुई है। टाटा मोटर्स ने अगले 12 महीनों में आईसीई और ईवी मॉडल सहित सात नए वाहन उतारने की योजना बनाई है। नोमुरा ने कहा, 'दीर्घ अवधि में प्रबंधन को उम्मीद है कि वाहन उद्योग वास्तविक सकल घरेलू उत्पाद के 1-1.5 गुना या लगभग 6-8 प्रतिशत सालाना दर से बढ़ेगा। टाटा मोटर्स पीवी खंड मजबूत परिचालन, विविध वाहनों और जनवरी 2026 में कीमते बढ़ाने की अपनी योजना के दम पर दीर्घ अवधि में दो अंक का एडिटा मार्जिन हासिल करना चाहती है।'

हैरियर, सफारी के लिए बदली रणनीति

अंजलि सिंह
मुंबई, 1 अक्टूबर

वाहन विनिर्माता टाटा मोटर्स ने अपनी हैरियर और सफारी गाड़ियों के लिए रणनीति में बदलाव किया है। अब कंपनी इन गाड़ियों की वेरिएंट कम कर आधा कर दिया है और कम शुरुआती कीमत पर नए एडवेंचर एक्स ट्रिप्स मॉडल उतारा है। कंपनी का मकसद लाइन अप की जटिलता कम करना और एसयूवी खंड में पहुंच बढ़ाना है। हैरियर अब छह वेरिएंट में मौजूद है। पहले इसके 11 वेरिएंट थे और कंपनी ने सफारी के भी 11 से घटाकर 5 वेरिएंट कर दिए हैं। कंपनी ने कहा कि पहले की व्यक्ति आधारित वेरिएंट रणनीति से काफी जटिलताएं सामने आ रही थीं और इससे खरीदार भी भ्रमित हो रहे थे। जिसके बाद हमने एक साल लाइन अप को दोबारा पेश किया। टाटा मोटर्स के प्रवक्ता ने कहा, 'हैरियर और सफारी के आमतौर पर मांग मिड और हाई ट्रिप्स में केंद्रित रही है, जहां ग्राहक सुविधाओं के साथ आराम तलाशते हैं। पुनर्गठित लाइन अप और एडवेंचर एक्स वेरिएंट के साथ हम कम कीमत पर वही सुविधाएं पेश कर रहे हैं।' कंपनी के अधिकारियों ने बताया कि एडवेंचर एक्स ट्रिप्स से बिक्री बढ़ने की उम्मीद है। हालांकि, पिछले साल के मुकाबले बिक्री का औसत मूल्य कम हो सकता

है, जब उच्च वेरिएंट की मांग अधिक थी। हर महीने कुल मिलाकर औसतन 4,500 से 5,000 तक हैरियर और सफारी की बिक्री होती है। हाल ही में वस्तु एवं सेवा कर की दरें कम होने भीसे कीमतों में कमी आई है। अब हैरियर की शुरुआती कीमत 14.99 लाख रुपये से घटकर 13.99 लाख रुपये (एक्स-शोरूम) हो गई है, जबकि सफारी की शुरुआती कीमत 15.49 लाख रुपये से कम होकर 14.66 लाख रुपये हो गई है। 18.99 लाख में रुपये में पहले पेश की गई हैरियर एडवेंचर एक्स की कीमत अब 17.96 लाख रुपये हो गई है और सफारी एडवेंचर एक्स+ की कीमत भी 19.99 लाख रुपये से घटकर 18.90 लाख रुपये हो गई है।

टाटा मोटर्स के यात्री और इलेक्ट्रिक वाहनों के मुख्य वाणिज्यिक अधिकारी विवेक श्रीवत्स ने कहा, 'पिछले साल हमारे ग्राहक फीचर्स तो चाहते थे ऊंची कीमत देने के लिए तैयार नहीं थे। आपूर्ति श्रृंखला में लाइन अप कम कर और फीचर्स देकर हमने कम कीमतों के साथ इस सेगमेंट में एक बार फिर प्रवेश किया है। हम हैरियर और सफारी के मिड और एंट्री वर्जन में और अधिक खरीदारों को जोड़ते हुए ऊंचे ग्राहकों को बरकरार रखेंगे, जिससे मात्रात्मक वृद्धि होगी।' यह पुनर्गठन ऐसे समय में हो रहा है जब एसयूवी घरेलू बाजार में सबसे तेजी से बढ़ती श्रेणियों में से एक बनी हुई है।

सितंबर में कारों की बिक्री...

पृष्ठ 1 का शेप

मासुति की हाल में लॉन्च एसयूवी विक्टोरिक्स के लिए 25,000 बुकिंग मिली है। टाटा मोटर्स के पैसेंजर व्हीकल्स के प्रबंध निदेशक शैलेश चंद्रा ने कहा कि जीएसटी 2.0 के लागू होने के बाद उद्योग में मांग तेजी से बढ़ी है और त्योहारी सीजन से भी मांग को बल मिला है। सितंबर में टाटा मोटर्स ने 60,907 कारें बेचीं जो पिछले साल इसी महीने की तुलना में 47 फीसदी अधिक है। चंद्रा ने कहा कि इलेक्ट्रिक वाहन

की बिक्री में 96 फीसदी बढ़कर 9,191 वाहन हो गई और सीएनजी कारों की बिक्री 17,800 वाहन को पार कर गई जो पिछली तिमाही की तुलना में 105 फीसदी से अधिक है। इस बीच बनर्जी ने बताया कि भारी मांग के बीच लॉजिस्टिकल बाधाएं थीं। कारखानों से डीलरशिप को नई खेप जीएसटी कटौती लागू होने के दिन 22 सितंबर से वाहन भेजना शुरू हुई। उन्होंने कहा कि ट्रकों को एक फर्रा लगाने में लगभग 20 दिन लग जाते हैं। उन्होंने कहा कि उम्मीद है कि 10 अक्टूबर तक लॉजिस्टिक्स सामान्य हो जाएगा।

महिंद्रा ने भी इस समस्या का जिक्र किया। महिंद्रा ऑटोमोटिव इकाई के सीईओ नुल्लिनीकांत गोल्लागुंटा ने कहा, 'त्योहारी मांग में वृद्धि ने देशरो की उपलब्धता की समस्या पैदा कर दी है। हम अपने डीलर नेटवर्क को आपूर्ति बढ़ाने पर काम कर रहे हैं। उन्होंने कहा कि सितंबर में महिंद्रा की बिक्री 16 फीसदी बढ़कर 1,00,298 वाहन रही। एसयूवी की बिक्री 10 फीसदी बढ़ी है। नवरात्रि के पहले नौ दिनों के दौरान एसयूवी खंड में 60 फीसदी से अधिक की वृद्धि देखी गई। कमर्शियल वाहन खंड में 70 फीसदी से अधिक की वृद्धि हुई है।

कर्नाटक में हेलीकॉप्टर बनाएंगी एयरबस और टाटा

एयरबस और टाटा एडवॉंस्ड पहली निजी क्षेत्र की हेलीकॉप्टर सिस्टम्स लिमिटेड (टीएएसएल) फाइनल असेंबली लाइन (एफएएल) स्थापित करेंगी। दोनों कंपनियों ने बुधवार को यह घोषणा की है। इस एफएएल में एयरबस एच125 हेलीकॉप्टर बनाए जाएंगे।

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT

Q-LINE BIOTECH LIMITED

CIN: U74120UP2010PLC042528

Our Company was originally incorporated as “POCT Services Private Limited” on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to “Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to “Q-Line Biotech Limited”, and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled **“History and Corporate Structure”** beginning on page 149 of the Draft Red Herring Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012
Tel.: +91 522-2435570, **E-mail:** compliance@qlinebiotech.com, **Website:** www.qlinebiotech.com
Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer

OUR PROMOTERS: Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal

“THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (“NSE EMERGE”).”

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 70,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE “EQUITY SHARES”) OF Q-LINE BIOTECH LIMITED (“OUR COMPANY” OR “QLBL” OR “THE ISSUER”) AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹ (●) PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ (●) LAKHS (“PUBLIC ISSUE”) OUT OF WHICH (●) EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING ₹ (●) LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE “MARKET MAKER RESERVATION PORTION”). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF (●) EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ (●) LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET ISSUE”. THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE (●) % AND (●) % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, MAY CONSIDER A PRE-IPO PLACEMENT OF UP TO 8,00,000 EQUITY SHARES FOR CASH CONSIDERATION (“PRE-IPO PLACEMENT”) PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS. IF THE PRE-IPO PLACEMENT IS UNDERTAKEN, THE NUMBER OF EQUITY SHARES ISSUED PURSUANT TO THE PRE-IPO PLACEMENT SHALL BE REDUCED FROM THE ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B)(i) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED (“SCRR”).

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLMS AND WILL BE ADVERTISED IN ALL EDITION OF (●) (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND ALL EDITION OF (●) (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND HINDI EDITION OF (●), REGIONAL NEWSPAPER (HINDI BEING THE REGIONAL LANGUAGE OF LUCKNOW WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF NSE (“NSE EMERGE”) FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least 3 additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of 1 Working Day, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLMs and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank. The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers (“QIBs”, the “QIB Portion”), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“Anchor Investor Portion”), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (of which one third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs) and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders who applies for minimum application size, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective ASBA accounts, and UPI ID in case of bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see **“Issue Procedure”** beginning on page 344 of the Draft Red Herring Prospectus.

This public announcement is made in compliance with the provisions of Regulation 247(2) of the SEBI ICDR Regulations, to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares of face value of ₹ 10 each pursuant to the issue and the Draft Red Herring Prospectus dated September 30, 2025 has been filed with the SME Platform of NSE (“NSE Emerge”) on September 30, 2025. The Draft Red Herring Prospectus filed with NSE Emerge shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#sme_offer, on the website of the BRLMs at www.hemsecurities.com and www.shareindia.com and also on the website of the Company www.qlinebiotech.com. Our Company invites public to give comments on the Draft Red Herring Prospectus filed with NSE Emerge with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of our Company, and/or to the BRLMs at their respective addresses mentioned below. All comments must be received by our Company and/or the Company Secretary & Compliance Officer of our Company, and/or to the BRLMs in relation to the issue on or before 5.00 p.m. on the 21st day from the aforementioned date of filing of the Draft Red Herring Prospectus with NSE Emerge.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to **“Risk Factors”** on page 29 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the Registrar of Companies (“RoC”) and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of NSE (“NSE Emerge”). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see **“Capital Structure”** beginning on page 71 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see **“History and Corporate Structure”** beginning on page 149 of the Draft Red Herring Prospectus.

The BRLMs associated with the Issue have handled 87 Public Issues in the past three years, out of which 8 issues were closed below the Issue/ Offer Price on listing date:

| Name of BRLM | Total Issue | | Issue closed below IPO Price on listing date |
|--|-------------|-----|--|
| | Mainboard | SME | |
| Hem Securities Limited | 2 | 66 | 3 (SME) |
| Share India Capital Services Private Limited | - | 18 | 5 |
| Common* | - | 1 | - |
| Total | 2 | 85 | 8 |

*Issues in which both BRLMs were involved.

| BOOK RUNNING LEAD MANAGERS TO THE ISSUE | | REGISTRAR TO THE ISSUE |
|--|--|---|
| <h2>Hem Securities</h2> | <h2>Share India</h2> <p>You generate, we multiply</p> | <h2>Purva Sharegistry</h2> |
| HEM SECURITIES LIMITED Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai - 400013, Maharashtra, India Tel. No.: +91- 22- 49060000; Email: ib@hemsecurities.com Investor Grievance Email: redressal@hemsecurities.com Website: www.hemsecurities.com Contact Person: Sourabh Garg, VP SEBI Regn. No.: INM000010981 | SHARE INDIA CAPITAL SERVICES PRIVATE LIMITED Address: A-25, Basement, Sector-64, Noida, Gautam Buddha Nagar, 201301, Uttar Pradesh, India Tel No.: +91 0120-6483000 Email: mb@shareindia.com Website: www.shareindia.com Contact Person: Kunal Bansal SEBI Reg. No.: INM000012537 | PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011 Tel. No.: 91 22 2301 2517 / 8261 Fax No.: +91-022-23012517 Email: support@purvashare.com Website: www.purvashare.com Contact Person: Deepali Dhuri SEBI Registration No.: INR000001112 |

| COMPANY SECRETARY & COMPLIANCE OFFICER | |
|---|--|
| Akhand Pratap Singh , Company Secretary & Compliance Officer, Tel.: +91 522-2435570, E-mail: akhand.singh@qlinebiotech.com, Website: www.qlinebiotech.com Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012 | |

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Red Herring Prospectus.

| For Q-Line Biotech Limited On behalf of the Board of Directors | |
|---|--|
| | Akhand Pratap Singh Company Secretary and Compliance Officer |

Disclaimer: Q-Line Biotech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on September 30, 2025. The Draft Red Herring Prospectus is available on the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#sme_offer and is available on the websites of the BRLMs at www.hemsecurities.com and www.shareindia.com and also on the website of the Company www.qlinebiotech.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled “Risk Factors” beginning on page 29 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in “offshore transactions” in reliance on Regulation “S” under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

॥ संक्षिप्त समाचार

आपदा में बह गई खुशियां, इस साल कैसे मनाएं त्योहार...बेबस लोगों ने बताई आपबीती



देहरादून, एजेंसी। बीते दिनों हुई मानसून की बारिश लोगों को गहरे जख्म दे गई। राजकीय प्राथमिक विद्यालय चौका चूंगा चामासारी में बच्चों की पाठशाला चल रही है। कुछ बच्चे विद्यालय के मैदान में खेल रहे हैं। आगे जाते ही मजाडा का वो रास्ता आ गया, जिसे आपदा अपने साथ बहा ले गई थी। पता नहीं वो कौन से घड़ी थी, जब हमारे गांव में ऐसी बारिश हुई। मानसून खत्म होने से पहले ग्रामीण नवरात्र और दीपावली की खरीदारी के लिए योजना बना रहे थे लेकिन अब हम कैसे अपना यह त्योहार मनाएं, जब हमारी खुशियां ही आफत की उस बारिश में बह गई हैं। इससे पहले राजकीय प्राथमिक विद्यालय चौका चूंगा चामासारी में बच्चों की पाठशाला चल रही है। कुछ बच्चे विद्यालय के मैदान में खेल रहे हैं। आगे जाते ही मजाडा का वो रास्ता आ गया, जिसे आपदा अपने साथ बहा ले गई थी। जेसीबी मशीन से मलवे को हटाने का काम किया जा रहा है। कुछ दिन पहले ही साफ हुए रास्ते से होते हुए ग्रामीण अपने गांव तक पहुंच रहे हैं। उधर आपदा के 15 दिन बाद स्थिति में थोड़ा तो सुधार आया है, लेकिन ग्रामीणों के चेहरे पर वह खुशी नहीं है, जो पहले पहले देखी जाती थी। ग्रामीण मलबे में दबे अपने गांव में बस इसलिए जा रहे हैं, ताकि वह अपने पशुओं के लिए चारा पत्ती की व्यवस्था कर सकें। इसके अलावा घरों में दबा सामान भी उन्हें मिल सके। लेकिन इसमें भी ग्रामीणों को मायूसी ही हाथ लग रही है। शाम होने से पहले ग्रामीण अपने घरों व अपने परिजनों के घरों के लिए निकल गए हैं। जिससे अंधेरे में कोई पेशानी न हो।

चार दिन में दो हाथियों की मौत हरिद्वार वन प्रभाग में खलबली सैंपल जांच को आईवीआरआई को भेजा



देहरादून, एजेंसी। चार दिन में दो हाथियों की मौत होने से आईवीआरआई को सैंपल जांच के लिए भेजा गया। पानी के सैंपल भी लिए गए। खेतों से फैसिंग हटाने का भी अभियान चलेगा। हरिद्वार वन प्रभाग में चार दिनों में दो हाथियों की मौत खेत में लगी तारबाड़ में करंट से हुई जबकि दूसरे की मौत का कारण स्पष्ट नहीं है। हाथी की मौत के बाद वन विभाग ने अभियान चलाने की योजना बनाई है, जिसमें संबंधित इलाकों में जंगल से सटे खेतों में इस तरह की फैसिंग को हटाय जाएगा। इसके अलावा आसपास के जल स्रोतों से पानी के सैंपल भी जांच के लिए गए हैं। हरिद्वार वन प्रभाग में 26 सितंबर को खानपुर रेंज में रसूलपुर और 29 को शाह मंसूर बीट में एक हाथी का शव मिला। इसके बाद से वन महकमे में खलबली मची हुई है। रसूलपुर बीट में वन और राजस्व विभाग की सीमा पर हाथी का शव मिला था। इसके मौत के कारणों को लेकर अस्पष्टता होने के कारण सैंपल को जांच के लिए आईवीआरआई बरेली भेजा गया है। शाह मंसूर में खेत में हाथी का शव मिला है, यहां पर खेत में इलेक्ट्रिक फैसिंग लगी थी। मामले के दो मालिक के खिलाफ मुकदमा दर्ज किया गया है। डीएफओ स्वप्निल अनिरुद्ध कहते हैं कि दूसरे मामले में खेत में शव मिला है, इसमें हाथी की मौत का कारण बिजली का करंट लग रहा है। इसके बाद खेत मालिक के खिलाफ मुकदमा दर्ज किया गया है। पहले हाथी की मौत के कारणों को लेकर स्पष्टता नहीं है जिसके कारण सैंपल को जांच के लिए आईवीआरआई बरेली व भारतीय वन जीव संस्थान देहरादून भेजा गया है, जिसमें विष समेत अन्य कारणों का भी पता किया जा सके। घटना स्थल के आसपास के क्षेत्र से पानी के सैंपल भी लिए गए हैं। दूसरी घटना जहां पर हुई है, उसके आसपास बड़े स्तर पर इलेक्ट्रिक फैसिंग होने का पता चला है, ऐसे में एक बड़ी टीम के माध्यम से इन फैसिंग को हटाने का अभियान शुरू किया जाएगा। साथ ही मामले की जांच एसडीओ स्तर के अधिकारी को सौंपी गई है।

कांग्रेस कार्यकर्ताओं ने किया जल संस्थान के कार्यालय का घेराव

देहरादून, एजेंसी। कांग्रेस कार्यकर्ताओं ने जल संस्थान कार्यालय का घेराव किया। कार्यकर्ताओं ने नारेबाजी करके संस्थान के अधिकारियों को अपनी कार्यशैली में सुधार लाने की चेतावनी दी। अधिकारियों पर उपभोक्ताओं के साथ अभद्रता करने का आरोप लगाते हुए शासन से अधिकारियों के विरुद्ध कार्रवाई करने की मांग की। कांग्रेस के पूर्व जिलाध्यक्ष व नवाबगढ़ क्षेत्र के जिला पंचायत सदस्य संजय किशोर के नेतृत्व में जल संस्थान कार्यालय पहुंचे कार्यकर्ताओं ने हंगामा किया। जिला पंचायत सदस्य ने कहा कि पानी के बिल व अन्य समस्या को लेकर कार्यालय पर आ रहे उपभोक्ताओं के साथ अधिकारी अभद्रता कर रहे हैं। हाल में ग्राम पंचायत रुद्रपुर से प्रधान पद के लिए चुनाव लड़ चुके अभिराजन बिल की समस्या लेकर जल संस्थान के कार्यालय पहुंचे थे। उन्होंने आरोप लगाया कि जल संस्थान के अधिकारियों ने न सिर्फ उनके साथ अभद्रता की बल्कि उन्हें जेल भिजवाने तक की धमकी दी।

यूकेएसएसएससी पेपर लीक सीएम धामी के आश्वासन से संतुष्ट नहीं विपक्ष

देहरादून, एजेंसी। मुख्यमंत्री पुष्कर सिंह धामी ने यूकेएसएसएससी (उत्तराखंड अधीनस्थ चयन आयोग) पेपर लीक मामले की सीबीआई जांच की संस्तुति की घोषणा कर दी है। वहीं सीएम धामी से आश्वासन मिलने के बाद आठ दिनों से जांच सीबीआई से कराये जाने को लेकर संशय बरकरार है। क्योंकि भारतीय जनता पार्टी के ही मुख्यमंत्री रहे त्रिवेद सिंह रावत ने एनएच-74 घोटाले की जांच सीबीआई से कराने की घोषणा विधानसभा में खड़े होकर की थी।



धरने पर बैठे बेरोजगारों युवाओं ने भी अपना आंदोलन स्थगित कर दिया है। इसके बावजूद भी मुख्य विपक्षी पार्टी कांग्रेस संतुष्ट नजर नहीं आ रही है। कांग्रेस ने पेपर लीक मामले पर तीन अक्टूबर को मुख्यमंत्री आवास कूच किए जाने के प्रस्तावित कार्यक्रम को यथावत रखा है। कांग्रेस ने अपने पूर्व घोषित सीएम आवास कूच के कार्यक्रम को 3 अक्टूबर को पूरे जोर शोर से करने का आह्वान किया है। उत्तराखंड में विपक्ष की भूमिका निभा रही कांग्रेस का कहना है कि मुख्यमंत्री ने सोमवार को आंदोलनरत युवाओं के धरने पर पहुंचकर स्नातक स्तरीय पेपर लीक मामले की सीबीआई जांच की संस्तुति की है, लेकिन अब भी पेपर लीक मामले की सीएम त्रिवेद सिंह रावत ने कहा था कि एनएच-74 घोटाले की जांच 15 दिन में सीबीआई अपने हाथों में ले लेगी, लेकिन आठ साल बीतने के बावजूद यह जांच सीबीआई अपने हाथों में लेने के लिए अभी तक नहीं आई। उत्तराखंड कांग्रेस के प्रदेश उपाध्यक्ष सूर्यकांत धस्माना का कहना है कि पहले दिन से ही कांग्रेस यूकेएसएसएससी की भर्ती परीक्षा पेपर लीक की जांच हाईकोर्ट के सीटिंग जज की निगरानी में सीबीआई से करवाने की मांग कर रही है। साथ ही उनकी मांग है कि भर्ती परीक्षा के दौरान को पेपर लीक हुआ है, उस परीक्षा को निरस्त करके पुनः परीक्षा की नई तिथि घोषित की जाए।

शराब में मिलावट की जांच को होगी लैब टेस्टिंग, आय संसाधन बढ़ाने को उत्तराखंड सरकार ने उठाए कदम

देहरादून, एजेंसी। प्रदेश में बन रही शराब में मिलावट की शिकायतों की जांच के लिए शराब की लैब टेस्टिंग होगी। इससे ऐसी शिकायतों का प्रभावी समाधान हो सकेगा और राजस्व भी बढ़ेगा। राजस्व सपरस राज्य का अपना दर्जा वित्तीय वर्ष 2025-26 में बरकरार रखने को उत्तराखंड आय संसाधन बढ़ाने के लिए इसी प्रकार पूरी ताकत उठाएंगे।



मुख्यमंत्री पुष्कर सिंह धामी के विशेष निर्देशों के क्रम में राजस्व प्राप्ति से संबंधित विभागों को आय बढ़ाने की कार्ययोजना थमाई गई है। राजस्व बढ़ाने अथवा वसूल करने में ढीला प्रदर्शन कर रहे विभागों को खामियां दुरुस्त कर नये स्रोत ढूंढने और सुधारात्मक कदम उठाने को कहा गया है। जीएसटी के बाद आबकारी राज्य की आय का दूसरा सबसे बड़ा स्रोत है। आबकारी विभाग ने 5060 करोड़ के लक्ष्य को पाने से ही हाथ खड़े कर दिए हैं। शुरुआती चार महीनों में विभाग लक्ष्य का 31 प्रतिशत ही वसूल कर पाया। विभागीय अधिकारियों के अनुसार मात्र 4800 करोड़ ही अर्जित कर पाएंगे। बताया गया कि प्रदेश में निर्मित मदिरा में मिलावट की शिकायतें मिल रही हैं। इससे उपभोक्ता बाहर की शराब को प्राथमिकता दे रहे हैं। मुख्य सचिव आनंद बर्द्धन ने बताया कि इन शिकायतों पर रोकने लगाने को इसकी लैब टेस्टिंग की जाएगी।

वृद्धजन दिवस पर मुख्यमंत्री ने वरिष्ठ नागरिकों को किया सम्मानित, कई योजनाओं की दी सौगात



देहरादून, एजेंसी। अंतरराष्ट्रीय वृद्धजन दिवस पर सीएम धामी द्वारा वरिष्ठ नागरिकों को सम्मानित किया गया। इस दौरान उन्होंने कई योजनाओं की भी सौगात दी। अंतरराष्ट्रीय वृद्धजन दिवस के अवसर पर मुख्यमंत्री पुष्कर सिंह धामी ने बुधवार को हिमालयन सांस्कृतिक केंद्र, नौबुवाला में आयोजित राज्य स्तरीय कार्यक्रम में प्रतिभाग किया। इस मौके पर उन्होंने प्रदेशवासियों को वृद्धजन दिवस की शुभकामनाएं दीं और वरिष्ठ नागरिकों को सम्मानित कर "वरिष्ठ नागरिक सम्मान संकल्प" भी दिलाया। मुख्यमंत्री ने कार्यक्रम स्थल पर एक पेड़ को नाम अभियान के तहत पोषारोपण किया। उन्होंने वरिष्ठ नागरिकों की सेवा के लिए समर्पित निशुल्क एंबुलेंस वैन को हरी झंडी दिखाकर रवाना किया, साथ ही वाकथन रैली का शुभारंभ भी किया। मुख्यमंत्री धामी ने कहा कि वरिष्ठ नागरिक हमारे समाज की नींव हैं, जिनका अनुभव समाज को दिशा देता है। उन्होंने बताया कि राज्य व केंद्र सरकार मिलकर बुजुर्गों के लिए अटल वयोअभ्युदय योजना, प्रधानमंत्री वय वंदना योजना, राष्ट्रीय वयोशी योजना व वृद्धावस्था पेंशन योजना जैसी कई योजनाएं चला रही हैं। वर्तमान में राज्य के करीब 6 लाख वरिष्ठ नागरिकों को डीबीटी के माध्यम से पेंशन दी जा रही है। उन्होंने कहा कि बागेश्वर, चमोली और उत्तरकाशी में वृद्धाश्रम संचालित हो रहे हैं, जबकि देहरादून, अल्मोड़ा और चंपावत में भवन निर्माण कार्य जारी है। रुद्रपुर में मॉडल वृद्धाश्रम और अन्य जिलों में भी निर्माण प्रक्रिया चल रही है। मुख्यमंत्री ने बताया कि जेरियेट्रिक केयर गिवर प्रशिक्षण कार्यक्रम के तहत 150 प्रशिक्षित केयर गिवर तैयार किए जा रहे हैं। वहीं, 1,300 वरिष्ठ नागरिकों की निशुल्क मोबिलिटी सर्विस भी प्रस्तावित है। वृद्धजन अधिकारों की रक्षा के लिए भरण-पोषण अधिनियम भी राज्य में लागू है।

गंभीर आर्थिक संकट से जूझ रहा परिवहन निगम

अधिकारियों, कर्मचारियों की छुट्टियां की रद्द

देहरादून, एजेंसी। पिछले महीनों में अधिक बारिश, आपदा, मार्ग बंद होने व अन्य कारणों से निगम की बस संचालन नहीं हो पाया। इस कारण परिवहन निगम में वित्तीय स्थिति अत्यंत खराब हो गई। कर्मचारियों को समय से वेतन नहीं मिल पा रहा है। गंभीर आर्थिक संकट से जूझ रहे परिवहन निगम प्रबंधन ने सभी अधिकारियों, कर्मचारियों की छुट्टियां रद्द कर दी हैं। निगम प्रबंधन का कहना है कि सब मिलकर काम करेंगे तो ही वेतन देने जैसे हालात बन सकेंगे। निगम के महाप्रबंधक संचालन क्रांति सिंह ने मंगलवार को सभी मंडलीय प्रबंधकों व अधिकारियों को पत्र जारी किया। उन्होंने कहा कि पिछले महीनों में अधिक बारिश, आपदा, मार्ग बंद होने व अन्य कारणों से निगम की बस संचालन नहीं हो पायाइ इस कारण वित्तीय स्थिति अत्यंत खराब हो गई। कर्मचारियों को समय से वेतन नहीं मिल पा रहा है।

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



Q-LINE BIOTECH LIMITED

CIN: U74120UP2010PLC042528

Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled **"History and Corporate Structure"** beginning on page 149 of the Draft Red Herring Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012
Tel.: +91 522-2435570, E-mail: compliance@qlinebiotech.com, Website: www.qlinebiotech.com
Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer

OUR PROMOTERS: Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal

“THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (“NSE EMERGE”).”

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 70,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE “EQUITY SHARES”) OF Q-LINE BIOTECH LIMITED (“OUR COMPANY” OR “QLBL” OR “THE ISSUER”) AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹ (●) PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ (●) LAKHS (“PUBLIC ISSUE”) OUT OF WHICH (●) EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING ₹ (●) LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE “MARKET MAKER RESERVATION PORTION”), THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF (●) EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ (●) LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET ISSUE”. THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE (●) % AND (●) % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, MAY CONSIDER A PRE-IPO PLACEMENT OF UP TO 8,00,000 EQUITY SHARES FOR CASH CONSIDERATION (“PRE-IPO PLACEMENT”) PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS. IF THE PRE-IPO PLACEMENT IS UNDERTAKEN, THE NUMBER OF EQUITY SHARES ISSUED PURSUANT TO THE PRE-IPO PLACEMENT SHALL BE REDUCED FROM THE ISSUE. SUBJECT TO COMPLIANCE WITH RULE 19(2)(B)(I) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED (“SCRR”). THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLMS AND WILL BE ADVERTISED IN ALL EDITION OF (●) (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND ALL EDITION OF (●) (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND HINDI EDITION OF (●) REGIONAL NEWSPAPER (HINDI BEING THE REGIONAL LANGUAGE OF LUCKNOW WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF NSE (“NSE EMERGE”) FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE. In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least 3 additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of 1 Working Day, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLMs and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank. The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers (“QIBs”, the “QIB Portion”), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“Anchor Investor Portion”), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds or at above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (of which one third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs) and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders who applies for minimum application size, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective ASBA accounts, and UPI ID in case of bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see **“Issue Procedure”** beginning on page 344 of the Draft Red Herring Prospectus. This public announcement is made in compliance with the provisions of Regulation 247(2) of the SEBI ICDR Regulations, to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares of face value of ₹ 10 each pursuant to the Issue and the Draft Red Herring Prospectus dated September 30, 2025 has been filed with the SME Platform of NSE (“NSE Emerge”) on September 30, 2025. The Draft Red Herring Prospectus filed with NSE Emerge shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#nse_offer, on the website of the BRLMs at www.hemsecurities.com and www.shareindia.com and also on the website of the Company www.qlinebiotech.com. Our Company invites public to give comments on the Draft Red Herring Prospectus filed with NSE Emerge with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of our Company, and/or to the BRLMs at their respective addresses mentioned below. All comments must be received by our Company and/or the Company Secretary & Compliance Officer of our Company, and/or to the BRLMs in relation to the issue on or before 5.00 p.m. on the 21st day from the aforementioned date of filing of the Draft Red Herring Prospectus with NSE Emerge. Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to **“Risk Factors”** on page 29 of the Draft Red Herring Prospectus. Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the Registrar of Companies (“RoC”) and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Draft Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of NSE (“NSE Emerge”). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see **“Capital Structure”** beginning on page 71 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see **“History and Corporate Structure”** beginning on page 149 of the Draft Red Herring Prospectus. The BRLMs associated with the Issue have handled 87 Public Issues in the past three years, out of which 8 issues were closed below the Issue/ Offer Price on listing date:

| Name of BRLM | Total Issue | | Issue closed below IPO Price on listing date |
|--|-------------|-----|--|
| | Mainboard | SME | |
| Hem Securities Limited | 2 | 66 | 3 (SME) |
| Share India Capital Services Private Limited | - | 18 | 5 |
| Common* | - | 1 | - |
| Total | 2 | 85 | 8 |

*Issues in which both BRLMs were involved.

BOOK RUNNING LEAD MANAGERS TO THE ISSUE



Hem Securities



Share India

You generate, we multiply

HEM SECURITIES LIMITED

Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai - 400013, Maharashtra, India
Tel. No.: +91- 22- 49060000;
Email: lb@hemsecurities.com
Investor Grievance Email: redressal@hemsecurities.com
Website: www.hemsecurities.com
Contact Person: Sourabh Garg, VP
SEBI Regn. No.: INM00010981

SHARE INDIA CAPITAL SERVICES PRIVATE LIMITED

Address: A-25, Basement, Sector-64, Noida, Gautam Buddha Nagar, 201301, Uttar Pradesh, India
Tel No.: +91 0120-6483000
Email: mb@shareindia.com
Website: www.shareindia.com
Contact Person: Kunal Bansal
SEBI Reg. No.: INM000012537

PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED

Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011
Tel. No.: 91 22 2301 2517 / 8261
Fax No.: +91-022-23012517
Email: support@purvashare.com
Website: www.purvashare.com
Contact Person: Deepali Dhuri
SEBI Registration No.: INR000001112

COMPANY SECRETARY & COMPLIANCE OFFICER

Akhand Pratap Singh, Company Secretary & Compliance Officer,
Tel.: +91 522-2435570, E-mail: akhand.singh@qlinebiotech.com, Website: www.qlinebiotech.com
Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Red Herring Prospectus.

Place: Lucknow
Date: October 01, 2025

Akhand Pratap Singh
Company Secretary and Compliance Officer

For Q-Line Biotech Limited
On behalf of the Board of Directors

Sd/-
Akhand Pratap Singh
Company Secretary and Compliance Officer

Disclaimer: Q-Line Biotech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on September 30, 2025. The Draft Red Herring Prospectus is available on the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#nse_offer and is available on the websites of the BRLMs at www.hemsecurities.com and www.shareindia.com and also on the website of the Company www.qlinebiotech.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled “Risk Factors” beginning on page 29 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in “offshore transactions” in reliance on Regulation “S” under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.